These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29519921)

  • 1. Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial.
    Ebrahimi F; Giaglis S; Hahn S; Blum CA; Baumgartner C; Kutz A; van Breda SV; Mueller B; Schuetz P; Christ-Crain M; Hasler P
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of adjunct corticosteroids for community-acquired pneumonia in diabetic patients.
    Popovic M; Blum CA; Nigro N; Mueller B; Schuetz P; Christ-Crain M
    Diabetologia; 2016 Dec; 59(12):2552-2560. PubMed ID: 27614658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.
    Blum CA; Nigro N; Briel M; Schuetz P; Ullmer E; Suter-Widmer I; Winzeler B; Bingisser R; Elsaesser H; Drozdov D; Arici B; Urwyler SA; Refardt J; Tarr P; Wirz S; Thomann R; Baumgartner C; Duplain H; Burki D; Zimmerli W; Rodondi N; Mueller B; Christ-Crain M
    Lancet; 2015 Apr; 385(9977):1511-8. PubMed ID: 25608756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin to modify neutrophil function in older patients with septic pneumonia (SNOOPI): study protocol for a randomised placebo-controlled trial.
    Greenwood H; Patel J; Mahida R; Wang Q; Parekh D; Dancer RC; Khiroya H; Sapey E; Thickett DR
    Trials; 2014 Aug; 15():332. PubMed ID: 25146127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil extracellular traps are increased in patients with acute ischemic stroke: prognostic significance.
    Vallés J; Lago A; Santos MT; Latorre AM; Tembl JI; Salom JB; Nieves C; Moscardó A
    Thromb Haemost; 2017 Oct; 117(10):1919-1929. PubMed ID: 28837206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to antibiotics administration and outcome in community-acquired pneumonia: Secondary analysis of a randomized controlled trial.
    Marti C; John G; Genné D; Prendki V; Rutschmann OT; Stirnemann J; Garin N
    Eur J Intern Med; 2017 Sep; 43():58-61. PubMed ID: 28648477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials.
    Ebrahimi F; Wolffenbuttel C; Blum CA; Baumgartner C; Mueller B; Schuetz P; Meier C; Kraenzlin M; Christ-Crain M; Betz MJ
    Eur Respir J; 2019 Feb; 53(2):. PubMed ID: 30578395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the impact of an antimicrobial stewardship program on the length of stay of immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired pneumonia: A quasi-experimental study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Am J Infect Control; 2016 May; 44(5):e73-9. PubMed ID: 26899527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid treatment for community-acquired pneumonia--the STEP trial: study protocol for a randomized controlled trial.
    Blum CA; Nigro N; Winzeler B; Suter-Widmer I; Schuetz P; Briel M; Bingisser R; Zimmerli W; Ullmer E; Elsaesser H; Tarr P; Wirz S; Thomann R; Hofmann E; Rodondi N; Duplain H; Burki D; Mueller B; Christ-Crain M
    Trials; 2014 Jun; 15():257. PubMed ID: 24974155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent association of glucocorticoids with adverse outcome in community-acquired pneumonia: a 6-year prospective cohort study.
    Nickler M; Ottiger M; Steuer C; Kutz A; Christ-Crain M; Zimmerli W; Thomann R; Hoess C; Henzen C; Bernasconi L; Huber A; Mueller B; Schuetz P;
    Crit Care; 2017 Mar; 21(1):72. PubMed ID: 28335807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.
    Bordon JM; Fernandez-Botran R; Wiemken TL; Peyrani P; Uriarte SM; Arnold FW; Rodriquez-Hernandez L; Rane MJ; Kelley RR; Binford LE; Uppatla S; Cavallazzi R; Blasi F; Aliberti S; Restrepo MI; Fazeli S; Mathur A; Rahmani M; Ayesu K; Ramirez J
    Infection; 2015 Dec; 43(6):729-38. PubMed ID: 26424683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of care delivered by fee-for-service and DRG hospitals in Switzerland in patients with community-acquired pneumonia.
    Schuetz P; Albrich WC; Suter I; Hug BL; Christ-Crain M; Holler T; Henzen C; Krause M; Schoenenberger R; Zimmerli W; Mueller B
    Swiss Med Wkly; 2011; 141():w13228. PubMed ID: 21769757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis.
    Briel M; Spoorenberg SMC; Snijders D; Torres A; Fernandez-Serrano S; Meduri GU; Gabarrús A; Blum CA; Confalonieri M; Kasenda B; Siemieniuk RAC; Boersma W; Bos WJW; Christ-Crain M; ; ;
    Clin Infect Dis; 2018 Jan; 66(3):346-354. PubMed ID: 29020323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
    Lindstrom ST; Wong EK
    Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome.
    Polverino E; Cillóniz C; Dambrava P; Gabarrús A; Ferrer M; Agustí C; Prina E; Montull B; Menendez R; Niederman MS; Torres A
    Respirology; 2013 Feb; 18(2):263-71. PubMed ID: 23134361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease.
    Le Joncour A; Martos R; Loyau S; Lelay N; Dossier A; Cazes A; Fouret P; Domont F; Papo T; Jandrot-Perrus M; Bouton MC; Cacoub P; Ajzenberg N; Saadoun D; Boulaftali Y
    Ann Rheum Dis; 2019 Sep; 78(9):1274-1282. PubMed ID: 31147357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease.
    Ottiger M; Nickler M; Steuer C; Odermatt J; Huber A; Christ-Crain M; Henzen C; Hoess C; Thomann R; Zimmerli W; Mueller B; Schuetz P
    Eur J Intern Med; 2016 Dec; 36():67-73. PubMed ID: 27567042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.
    Viasus D; Garcia-Vidal C; Simonetti AF; Dorca J; Llopis F; Mestre M; Morandeira-Rego F; Carratalà J
    BMJ Open; 2015 Jan; 5(1):e006251. PubMed ID: 25564143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of soluble intercellular adhesion molecule-1 as a biomarker for disease severity of patients with community-acquired pneumonia.
    Chang PY; Tsao SM; Chang JH; Chien MH; Hung WY; Huang YW; Yang SF
    Clin Chim Acta; 2016 Dec; 463():174-180. PubMed ID: 27983998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.